Nephrocare Health Services Reports Strong Q2 Profit of Rs 335 Million

Revenue from operations reached Rs 3,033.98 million for the September 2026 quarter, up from Rs 2,457.18 million in the same period last year.
Profit for the quarter stood at Rs 335.31 million, marking a significant recovery from the Rs 94.74 million loss reported in Q2 of the previous fiscal year.

Reader Takeaway: Strong revenue growth and successful international acquisitions are driving profitability, though integration risks of new clinics remain.

What just happened

Nephrocare Health Services has declared its financial results for the quarter and half-year ended September 30, 2026. The firm recorded a consolidated profit of Rs 335.31 million for the quarter, reflecting a sharp improvement over the loss incurred in the same quarter last year. Revenue saw double-digit growth, rising from Rs 2,457.18 million to Rs 3,033.98 million year-on-year.

Why this matters

The transition to profitability highlights the success of the company’s current expansion strategy. By executing asset transfers in the Philippines and entering the Kazakhstan market, Nephrocare is diversifying its geographic footprint beyond India. The company also confirmed that Rs 2,147.85 million of its IPO proceeds have been utilized, with over Rs 1.1 billion still available to support further domestic clinic expansion.

Business and Operational Developments

The company has been active on the inorganic growth front. Between July and September, it signed ten asset transfer agreements in the Philippines costing Rs 926.49 million. It also initiated a move into Kazakhstan by acquiring Dialysis Center Almaty LLP for Rs 112.76 million. Furthermore, the company issued over 2.18 lakh shares under its employee stock grant scheme, signaling a focus on talent retention during this growth phase.

Risks to watch

While the company is scaling rapidly, investors should monitor the integration timeline for the newly acquired international assets. Managing operations across multiple jurisdictions—specifically in the Philippines and Kazakhstan—requires significant management bandwidth. Additionally, the effective deployment of the remaining Rs 1,103.68 million in IPO proceeds will be critical for maintaining growth momentum in the domestic market.

What to track next

Watch for updates on the operational performance of the newly acquired JCM Health Summit in the Philippines and progress on the rollout of new Indian clinics funded by the residual IPO capital.